Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects

  • FEBS Lett. 1997 Apr 7;406(1-2):33-6. doi: 10.1016/s0014-5793(97)00232-9.
A Renodon  1 ,  J L Boucher ,  M A Sari ,  M Delaforge ,  J Ouazzani ,  D Mansuy
Affiliations
  • 1. Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, URA 400 CNRS, Paris, France.
PMID: 9109381 DOI: 10.1016/s0014-5793(97)00232-9
Abstract

The ergot alkaloid bromocriptine (BKT) was found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC50 = 10 +/- 2 microM) whereas it was poorly active towards inducible macrophage NOS (IC50 > 100 microM). BKT affects the activation of NOS by Calmodulin, as it not only inhibits L-arginine oxidation to NO and L-citrulline but also NADPH oxidation and calmodulin-dependent cytochrome c reduction catalyzed by neuronal NOS. These results suggest that BKT could exert some of its therapeutic effects by interfering with the NOS-dependent formation of nitric oxide and/or superoxide ion in various tissues.

Products